fda warning letters compounded semaglutide tirzepatide 2024 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of The FDA has officially approved

Many users report decreased alcohol tolerance while on semaglutide

Buyer Takeaway 10: The published evidence points toward a four-part musculoskeletal protection strategy during GLP-1 therapy: baseline DXA measurement, resistance training at least twice weekly, adequate protein at every meal, and appropriate calcium/vitamin D

Orforglipron treatment was also associated with slower gastric emptying time and short-term weight loss, all of which are consistent with drug class effects , with up to 5.4 kg loss over 4 weeks in higher-dose cohorts

Biochemistry 42, 81638170

The addition of the glucagon receptor is what drives increased energy expenditure and fat burning beyond what GLP-1 and GIP activation alone can achieve